Copyright
©The Author(s) 2024.
World J Clin Oncol. May 24, 2024; 15(5): 635-643
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Table 1 Baseline characteristics, n (%)
Variable | All (63) | Excellent efficacy group (42) | Poor efficacy group (21) |
Age | 56 (51, 58) | 56 (50, 58) | 59 (50, 62) |
Sex | |||
Male | 34 (54.7) | 20 (47.6) | 14 (66.7) |
Female | 29 (45.3) | 22 (52.4) | 7 (33.3) |
ECOG-PS | |||
0 | 17 (27.0) | 12 (28.6) | 5 (23.8)) |
1 | 39 (61.9) | 26 (61.9) | 13 (61.9) |
2 | 7 (11.1) | 4 (9.5) | 3 (14.3) |
Disease status | |||
Unresectable | 55 (87.3) | 38 (90.5) | 17 (81.0) |
Recurrent | 8 (12.7) | 4 (9.5) | 4 (19.0) |
Number of organs involved | |||
1 | 40 (63.5) | 27 (64.3) | 13 (61.9) |
≥ 2 | 23 (36.5) | 15 (35.7) | 8 (38.1) |
HER2 status | |||
0 | 31 (49.2) | 17 (40.5) | 14 (66.7) |
1 | 15 (23.8) | 10 (23.8) | 5 (23.8) |
2 | 11 (17.5) | 11 (26.2) | 0 (0) |
Unmeasured | 6 (9.5) | 4 (9.5) | 2 (9.5) |
CPS | |||
0 | 8 (12.7) | 2 (4.8) | 6 (28.6) |
1 ≤ CPS < 5 | 11 (17.5) | 7 (16.7) | 4 (19.0) |
5 ≤ CPS < 10 | 12 (19.0) | 9 (21.4) | 3 (14.3) |
CPS ≥ 10 | 21 (33.3) | 18 (42.9) | 3 (14.3) |
Unmeasured | 11 (17.5) | 6 (14.3) | 5 (23.8) |
EBER | |||
Positive | 7 (11.1) | 6 (14.3) | 1 (4.8) |
Negative | 42 (66.7) | 26 (61.9) | 16 (76.2) |
Unmeasured | 14 (22.2) | 10 (23.8) | 4 (19.0) |
Table 2 Best overall response (patients with measurable lesions)
Group A (N = 42) | Group B (N = 21) | P value | |||
n (%) | 95%CI | n (%) | 95%CI | ||
Best overall response | |||||
Complete response (CR) | 0 | - | 0 | - | - |
Partial response (PR) | 30 (71.4) | - | 9 (42.9) | - | - |
Stable disease (SD) | 12 (28.6) | - | 10 (47.6) | - | - |
Progressive disease | 0 (0) | - | 2 (9.5) | - | - |
Overall response rate (CR + PR) | 30 (71.4) | 55.4-84.3 | 9 (42.9) | 21.8-66.0 | 0.03 |
Disease control rate (CR + PR + SD) | 42 (100) | 91.6-1.00 | 19 (90.5) | 69.6-98.8 | 2.527e-13 |
- Citation: Ma XT, Ou K, Yang WW, Cao BY, Yang L. Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer. World J Clin Oncol 2024; 15(5): 635-643
- URL: https://www.wjgnet.com/2218-4333/full/v15/i5/635.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i5.635